BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas

Head and Neck

Volumn 35, Issue 4, 2013, Pages 548-553

  Lee, Ji In ^a,b,c   Jang, Hye Won ^a   Kim, Sun Wook ^a   Kim, Jong Won ^a   Oh, Young Lyun ^a   Chung, Jae Hoon ^a  

^a Sungkyunkwan University   (South Korea)

^b Chung Ang University   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

BRAFV600E mutation; fine needle aspiration; papillary thyroid carcinoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ABLATION THERAPY; ADULT; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LOBECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THYROID CARCINOMA; THYROIDECTOMY; CARCINOMA; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PREVALENCE; PROGNOSIS; THYROID GLAND; THYROID TUMOR;

ADULT; BIOPSY, FINE-NEEDLE; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID GLAND; THYROID NEOPLASMS;

EID: 84875382648     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22997     Document Type: Article

References (39)

1. Hodgson NC, Button J, Solorzano CC,. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004; 11: 1093-1097.
2. National Cancer Centre K. 2002 annual report of the Korea Central Cancer Registry. Available at: http://www.ncc.re.kr. Accessed: February 2005.
3. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS,. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-1057; discussion 1057-1058.
4. Mazzaferri EL, Jhiang SM,. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
5. Gilliland FD, Hunt WC, Morris DM, Key CR,. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997; 79: 564-573.
6. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83: 1012-1021.
7. LiVolsi VA, Fadda G, Baloch ZW,. Prognostic factors in well-differentiated thyroid cancer. Rays 2000; 25: 163-175.
8. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004; 89: 2867-2872.
9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA,. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
10. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010; 95: 3693-3700.
11. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY,. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818-821.
12. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470; discussion 470-471.
13. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009; 56: 89-97.
14. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010; 95: 4197-4205.
15. O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010; 148: 1139-1145; discussion 1145-1146.
16. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588-593.
17. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-6379.
18. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-4090.
19. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-3949.
20. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 191-205.
21. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR,. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009; 253: 854-860.
22. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009; 16: 240-245.
23. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009; 27: 2977-2982.
24. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 2009; 19: 137-141.
25. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-368.
26. Lee JH, Lee ES, Kim YS,. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110: 38-46.
27. Lee JH, Lee ES, Kim YS, Won NH, Chae YS,. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 2006; 38: 201-204.
28. Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006; 107: 1831-1838.
29. Greene F, Page D, Fleming I, et al. American Joint Committee of Cancer: cancer staging manual. 6th ed. AJCC cancer staging handbook. New York: Springer-Verlag; 2002. pp 77-87.
30. Ito Y, Tomoda C, Uruno T, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 2006; 30: 91-99.
31. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006; 141: 489-494; discussion 494-496.
32. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006; 91: 3667-3670.
33. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466.
34. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13: 455-464.
35. Kim SK, Kim DL, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008; 17: 118-125.
36. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006; 65: 660-666.
37. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65: 4238-4245.
38. Liu D, Liu Z, Condouris S, Xing M,. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007; 92: 2264-2271.
39. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.